(NASDAQ: VTGN) Vistagen Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.
Vistagen Therapeutics's earnings in 2026 is -$62,236,000.On average, 7 Wall Street analysts forecast VTGN's earnings for 2026 to be -$75,574,545, with the lowest VTGN earnings forecast at -$80,120,472, and the highest VTGN earnings forecast at -$71,743,487. On average, 7 Wall Street analysts forecast VTGN's earnings for 2027 to be -$50,115,778, with the lowest VTGN earnings forecast at -$65,412,366, and the highest VTGN earnings forecast at -$33,176,179.
In 2028, VTGN is forecast to generate -$28,871,175 in earnings, with the lowest earnings forecast at -$31,351,489 and the highest earnings forecast at -$27,370,348.